Genomics and the second golden era of cancer drug development

Paul Workman1

  • 1Cancer Research UK Centre for Cancer Therapeutics, Sutton, UK. paul.workman@icr.ac.uk

Molecular Biosystems
|September 5, 2006
PubMed

Insights

The first era of cancer drug development yielded cytotoxic agents. The current, second golden era utilizes cancer genomics to guide new drug discovery and development.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • The 1940s marked the first golden era of cancer drug development, introducing cytotoxic agents.
  • Cytotoxic agents remain the cornerstone of contemporary cancer chemotherapy.
  • A paradigm shift is occurring in cancer treatment strategies.

Purpose of the Study:

  • To highlight the historical progression of cancer drug development.
  • To introduce the concept of a "second golden era" driven by genomics.
  • To emphasize the transformative potential of cancer genomics in directing future drug discovery.

Main Methods:

  • Historical analysis of cancer drug development milestones.
  • Review of current cancer treatment modalities.
  • Exploration of the role of genomic data in precision medicine.

Main Results:

  • The initial era produced broadly acting cytotoxic drugs.
  • The current era is characterized by a shift towards targeted therapies.
  • Genomic insights are increasingly informing the development of novel cancer therapeutics.

Conclusions:

  • Cancer genomics represents a new frontier in oncology drug development.
  • Personalized medicine approaches are becoming central to cancer care.
  • The integration of genomics promises more effective and tailored cancer treatments.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...